ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,163.67
-0.63%
Dow Jones
38,647.10
-0.17%
Gold vs US Dollar
2,307.205
0.20%
Brent Oil
82.215
0.29%
Bitcoin
67,073.00
0.47%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Entera Bio Ltd (ENTX)

  7. Entera Bio Ltd (ENTX) News

Entera Bio (ENTX)

Entera Bio Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ENTX
DateTimeSourceHeadlineSymbolCompany
07/06/202421:05Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ENTXEntera Bio Ltd
03/06/202413:00GlobeNewswire Inc.Entera Bio Reports Phase 1 Clinical Data of First-in-Class, Oral PTH(1-34) Peptide Candidate (EB612) for Patients with Hypoparathyroidism at ENDO 2024NASDAQ:ENTXEntera Bio Ltd
29/05/202421:08Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ENTXEntera Bio Ltd
15/05/202413:00GlobeNewswire Inc.Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board MemberNASDAQ:ENTXEntera Bio Ltd
13/05/202412:00GlobeNewswire Inc.Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024NASDAQ:ENTXEntera Bio Ltd
10/05/202421:14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ENTXEntera Bio Ltd
10/05/202421:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ENTXEntera Bio Ltd
10/05/202421:10GlobeNewswire Inc.Entera Bio Reports Q1 2024 Financial Results and Provides Business UpdatesNASDAQ:ENTXEntera Bio Ltd
08/04/202413:30GlobeNewswire Inc.Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral ResearchNASDAQ:ENTXEntera Bio Ltd
26/03/202412:30GlobeNewswire Inc.Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 MonthsNASDAQ:ENTXEntera Bio Ltd
20/03/202412:00GlobeNewswire Inc.Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel SyndromeNASDAQ:ENTXEntera Bio Ltd
08/03/202421:25Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ENTXEntera Bio Ltd
08/03/202421:12Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ENTXEntera Bio Ltd
08/03/202421:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ENTXEntera Bio Ltd
08/03/202421:05GlobeNewswire Inc.Entera Bio Announces Full Year 2023 Financial Results and Provides Business UpdatesNASDAQ:ENTXEntera Bio Ltd
04/03/202413:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ENTXEntera Bio Ltd
04/03/202413:30GlobeNewswire Inc.Entera Bio Regains Compliance with Nasdaq Minimum Bid Price RequirementNASDAQ:ENTXEntera Bio Ltd
15/02/202422:10Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ENTXEntera Bio Ltd
15/02/202405:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ENTXEntera Bio Ltd
14/02/202411:05Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:ENTXEntera Bio Ltd
02/02/202421:19Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ENTXEntera Bio Ltd
02/02/202421:17Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ENTXEntera Bio Ltd
30/01/202413:30GlobeNewswire Inc.Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:ENTXEntera Bio Ltd
16/01/202413:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENTXEntera Bio Ltd
11/01/202423:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENTXEntera Bio Ltd
03/01/202423:59Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENTXEntera Bio Ltd
03/01/202421:19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENTXEntera Bio Ltd
03/01/202421:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENTXEntera Bio Ltd
03/01/202421:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENTXEntera Bio Ltd
03/01/202413:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ENTXEntera Bio Ltd
 Showing the most relevant articles for your search:NASDAQ:ENTX

Your Recent History

LSE
GKP
Gulf Keystone Petroleum
LSE
ENET
Ethernity Networks
LSE
HE1
Helium One Global
LSE
TAVI
Tavistock Investments
LSE
MNL
Manchester & London Inve...
LSE
AWE
Alphawave Ip
LSE
SQZ
Serica Energy
LSE
BIRD
Blackbird
LSE
TUI
Tui
LSE
JET2
Jet2
LSE
SYME
Supply@me Capital
LSE
ARCM
Arc Minerals
LSE
GDR
Genedrive
LSE
CARD
Card Factory
LSE
SRSP
Sirius Petroleum
LSE
BOO
Boohoo
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved